Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969290198> ?p ?o ?g. }
- W1969290198 abstract "Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, ILIdentification of signaling pathways that are required for the growth and differentiation block of cells from adult acute myeloid leukemia (AML) is urgently required to facilitate development of novel therapies. Here, we describe an approach to functionally determine molecular drivers of AML by quantitative drug sensitivity and resistance testing (DSRT) of AML blast cells in primary culture ex vivo. The selection of drugs covered the entire cancer pharmacopeia and much of the pipeline of drugs under development in the industry: 120 FDA approved small molecular cancer drugs and 120 emerging drugs, investigational compounds and signal transduction inhibitors. All compounds were tested over a 10,000-fold concentration range to generate quantitative and reliable dose-response data. In addition, whole exome and transcriptome sequencing and phophoproteomic profiling were also performed to derive a comprehensive understanding of the molecular AML-related aberrations on an individual basis. Comparison of 17 AML patient samples and 3 healthy bone marrow control samples based on ex vivo drug responses identified several classes of approved and investigational drugs that showed selective anti-AML activities: mTOR inhibitors (e.g. temsirolomus, everolimus, sirolimus), MEK inhibitors (e.g. AS703026, GSK1120212, RDEA119, selumetinib), tyrosine kinase inhibitors (e.g. dasatinib, ponatinib, sunitinib), Bcl-2 inhibitors (navitoclax) and HSP90 inhibitors (e.g. BIIB021, NVP-AUY922, tanespimycin). In particular, the rapamycin class of mTOR inhibitors and allosteric MEK inhibitors stood out as effective and selective inhibitors in 8/17 (47%) and 9/17 (52%) of the patients, respectively. Simultaneous data from other targeted inhibitors made it possible to dissect the critical steps in signaling and therapeutic efficacy. For example, PI3K and Akt inhibitors were not effective in these patients, suggesting that the mTOR dependency is mediated through a PI3K-Akt-independent pathway. Similarly, the dependency of MEK signaling appears to be through a Ras-Raf-independent pathway since Raf inhibitors were not effective. In conclusion, the DSRT platform allows us to derive quantitative data on the ex vivo drug response profiles of AML cells from individual patients. This information could be used as a diagnostic tool to optimize personalized therapies in the future. Our data demonstrate that mTOR and MEK signaling and the associated inhibitors are the most promising leads for improved AML therapeutics. This analysis also demonstrates gaps in our current understanding of the redundancy of key cancer cell signaling pathways and proves the significant value of data from experimental drug response testing ex vivo.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 895. doi:1538-7445.AM2012-895" @default.
- W1969290198 created "2016-06-24" @default.
- W1969290198 creator A5001104871 @default.
- W1969290198 creator A5004930443 @default.
- W1969290198 creator A5008868111 @default.
- W1969290198 creator A5008928644 @default.
- W1969290198 creator A5016681267 @default.
- W1969290198 creator A5024066120 @default.
- W1969290198 creator A5032196301 @default.
- W1969290198 creator A5033369123 @default.
- W1969290198 creator A5034115001 @default.
- W1969290198 creator A5042781409 @default.
- W1969290198 creator A5043473901 @default.
- W1969290198 creator A5047848282 @default.
- W1969290198 creator A5050873337 @default.
- W1969290198 creator A5060810486 @default.
- W1969290198 creator A5061666924 @default.
- W1969290198 creator A5061939140 @default.
- W1969290198 creator A5064165646 @default.
- W1969290198 creator A5064764393 @default.
- W1969290198 creator A5067760174 @default.
- W1969290198 creator A5075634967 @default.
- W1969290198 creator A5076616453 @default.
- W1969290198 creator A5079229880 @default.
- W1969290198 creator A5089248994 @default.
- W1969290198 creator A5091008337 @default.
- W1969290198 date "2012-04-15" @default.
- W1969290198 modified "2023-09-26" @default.
- W1969290198 title "Abstract 895: Quantitative drug sensitivity and resistance testing (DSRT) of primary ex vivo AML blasts highlights mTOR and MEK as potential key molecular driver signals of therapeutic significance" @default.
- W1969290198 doi "https://doi.org/10.1158/1538-7445.am2012-895" @default.
- W1969290198 hasPublicationYear "2012" @default.
- W1969290198 type Work @default.
- W1969290198 sameAs 1969290198 @default.
- W1969290198 citedByCount "0" @default.
- W1969290198 crossrefType "proceedings-article" @default.
- W1969290198 hasAuthorship W1969290198A5001104871 @default.
- W1969290198 hasAuthorship W1969290198A5004930443 @default.
- W1969290198 hasAuthorship W1969290198A5008868111 @default.
- W1969290198 hasAuthorship W1969290198A5008928644 @default.
- W1969290198 hasAuthorship W1969290198A5016681267 @default.
- W1969290198 hasAuthorship W1969290198A5024066120 @default.
- W1969290198 hasAuthorship W1969290198A5032196301 @default.
- W1969290198 hasAuthorship W1969290198A5033369123 @default.
- W1969290198 hasAuthorship W1969290198A5034115001 @default.
- W1969290198 hasAuthorship W1969290198A5042781409 @default.
- W1969290198 hasAuthorship W1969290198A5043473901 @default.
- W1969290198 hasAuthorship W1969290198A5047848282 @default.
- W1969290198 hasAuthorship W1969290198A5050873337 @default.
- W1969290198 hasAuthorship W1969290198A5060810486 @default.
- W1969290198 hasAuthorship W1969290198A5061666924 @default.
- W1969290198 hasAuthorship W1969290198A5061939140 @default.
- W1969290198 hasAuthorship W1969290198A5064165646 @default.
- W1969290198 hasAuthorship W1969290198A5064764393 @default.
- W1969290198 hasAuthorship W1969290198A5067760174 @default.
- W1969290198 hasAuthorship W1969290198A5075634967 @default.
- W1969290198 hasAuthorship W1969290198A5076616453 @default.
- W1969290198 hasAuthorship W1969290198A5079229880 @default.
- W1969290198 hasAuthorship W1969290198A5089248994 @default.
- W1969290198 hasAuthorship W1969290198A5091008337 @default.
- W1969290198 hasConcept C121608353 @default.
- W1969290198 hasConcept C126322002 @default.
- W1969290198 hasConcept C143998085 @default.
- W1969290198 hasConcept C150903083 @default.
- W1969290198 hasConcept C207001950 @default.
- W1969290198 hasConcept C26291073 @default.
- W1969290198 hasConcept C2777413986 @default.
- W1969290198 hasConcept C2777583451 @default.
- W1969290198 hasConcept C2778729363 @default.
- W1969290198 hasConcept C2779490328 @default.
- W1969290198 hasConcept C2779536868 @default.
- W1969290198 hasConcept C2779699572 @default.
- W1969290198 hasConcept C2780381907 @default.
- W1969290198 hasConcept C502942594 @default.
- W1969290198 hasConcept C71924100 @default.
- W1969290198 hasConcept C86803240 @default.
- W1969290198 hasConcept C98274493 @default.
- W1969290198 hasConceptScore W1969290198C121608353 @default.
- W1969290198 hasConceptScore W1969290198C126322002 @default.
- W1969290198 hasConceptScore W1969290198C143998085 @default.
- W1969290198 hasConceptScore W1969290198C150903083 @default.
- W1969290198 hasConceptScore W1969290198C207001950 @default.
- W1969290198 hasConceptScore W1969290198C26291073 @default.
- W1969290198 hasConceptScore W1969290198C2777413986 @default.
- W1969290198 hasConceptScore W1969290198C2777583451 @default.
- W1969290198 hasConceptScore W1969290198C2778729363 @default.
- W1969290198 hasConceptScore W1969290198C2779490328 @default.
- W1969290198 hasConceptScore W1969290198C2779536868 @default.
- W1969290198 hasConceptScore W1969290198C2779699572 @default.
- W1969290198 hasConceptScore W1969290198C2780381907 @default.
- W1969290198 hasConceptScore W1969290198C502942594 @default.
- W1969290198 hasConceptScore W1969290198C71924100 @default.
- W1969290198 hasConceptScore W1969290198C86803240 @default.
- W1969290198 hasConceptScore W1969290198C98274493 @default.
- W1969290198 hasLocation W19692901981 @default.
- W1969290198 hasOpenAccess W1969290198 @default.
- W1969290198 hasPrimaryLocation W19692901981 @default.
- W1969290198 hasRelatedWork W1513939681 @default.
- W1969290198 hasRelatedWork W1598572484 @default.
- W1969290198 hasRelatedWork W1605988205 @default.
- W1969290198 hasRelatedWork W1974407724 @default.